(VIANEWS) – LNA SANTE (LNA.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| LNA SANTE (LNA.PA) | €19.40 | 2.54% | 9.08% |
| MEDISTIM (MEDI.OL) | kr181.00 | 2.36% | 27.12% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. LNA SANTE (LNA.PA)
2.54% Forward Dividend Yield and 9.08% Return On Equity
LNA Santé SA engages in the management and operation of health establishments. The company operates retirement homes, medical and rehabilitation care, home hospital, surgery, mental health clinic, and health center. LNA Santé SA was founded in 1990 and is based in Vertou, France.
Earnings Per Share
As for profitability, LNA SANTE has a trailing twelve months EPS of €2.28.
PE Ratio
LNA SANTE has a trailing twelve months price to earnings ratio of 8.51. Meaning, the purchaser of the share is investing €8.51 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.08%.
Volatility
LNA SANTE’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.22%, a negative 0.32%, and a positive 1.68%.
LNA SANTE’s highest amplitude of average volatility was 3.22% (last week), 1.61% (last month), and 1.68% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, LNA SANTE’s stock is considered to be overbought (>=80).
More news about LNA SANTE.
2. MEDISTIM (MEDI.OL)
2.36% Forward Dividend Yield and 27.12% Return On Equity
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr5.68.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 31.87. Meaning, the purchaser of the share is investing kr31.87 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.12%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
MEDISTIM’s EBITDA is 97.92.
Revenue Growth
Year-on-year quarterly revenue growth declined by 0.4%, now sitting on 526.36M for the twelve trailing months.
Moving Average
MEDISTIM’s worth is way under its 50-day moving average of kr207.18 and way under its 200-day moving average of kr222.82.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Apr 25, 2023, the estimated forward annual dividend rate is 4.5 and the estimated forward annual dividend yield is 2.36%.
More news about MEDISTIM.
